S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Accrual to this population is challenging, and the study was closed early because of feasibility. Although PFS was not statistically better with RCP, the hazard ratio was 0.51 and the lack of significance was likely due to small sample sizes. Notably, addition of ramucirumab to CP led to higher response rates than CP alone. Future research should consider exploring larger multicenter trials and other combinations to improve outcomes. Challenges in enrollment emphasize the need for innovative strategies and larger collaborations in rare malignancies such as thymic carcinoma.
Authors
- Jhanelle E. Gray (ORCID: https://orcid.org/0000-0003-1304-7062)
- Marianna Koczywas (ORCID: https://orcid.org/0000-0002-1588-6292)
- Tawee Tanvetyanon (ORCID: https://orcid.org/0000-0002-1287-1757)
- David R. Gandara (ORCID: https://orcid.org/0000-0003-1784-048X)
- Mary W. Redman (ORCID: https://orcid.org/0000-0003-2294-9674)
- T. Barbara (ORCID: https://orcid.org/0000-0002-6012-1168)
- Ying‐Qi Zhao (ORCID: https://orcid.org/0000-0002-2851-2257)
- Janet Tu (ORCID: https://orcid.org/0000-0002-1899-3501)
- Anne S. Tsao (ORCID: https://orcid.org/0000-0003-0505-6639)
- Martin J. Edelman (ORCID: https://orcid.org/0000-0002-3752-0726)
- Karen Kelly (ORCID: https://orcid.org/0000-0002-2235-6636)
- Jonathan Wesley Riess (ORCID: https://orcid.org/0000-0001-7370-7304)
- Ming-Hui Hsieh
Institutions
- Fox Chase Cancer Center (US)
- City Of Hope National Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Cornell University (US)
- Moffitt Cancer Center (US)
- Fred Hutch Cancer Center (US)
- Presbyterian Hospital (US)
- International Association for the Study of Lung Cancer (US)
- University of California, Davis (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100738
- Citations
- 4
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.48
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Ariad Pharmaceuticals
- Regeneron Pharmaceuticals
- Jazz Pharmaceuticals
- Novocure
- Astex Pharmaceuticals
- Janssen Scientific Affairs
- BeiGene
- Revolution Medicines
- G1 Therapeutics
- Coherus Biosciences
- National Institutes of Health
- Genentech
- EMD Serono
- Stand Up To Cancer
- Loxo Oncology
- Foundation Medicine
- National Cancer Institute
- Daiichi Sankyo Europe